Simcere Pharmaceutical Group (先声药业) has entered an agreement to pay 195.5 million RMB ($28.8 million) for a 37.5% stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd., a vaccine maker. Jiangsu Yanshen's major products include an influenza vaccine and a rabies vaccine (vero cell) for humans. The two products have the second and the fourth largest market shares in China respectively. Simcere did not release annual revenues for Jiangsu Yanshen. More details...

Stock Symbol: (NYSE: SCR)